These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38765679)

  • 1. PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistant
    Han Y; Zhang Y; Zhang X; Huang Z; Kong J; Wang X; Chen L; Wang Y; Cao J; Zhou T; Shen M
    Front Microbiol; 2024; 15():1291876. PubMed ID: 38765679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octominin: An antimicrobial peptide with antibacterial and anti-inflammatory activity against carbapenem-resistant Escherichia coli both in vitro and in vivo.
    Kong J; Wang Y; Han Y; Zhou H; Huang Z; Zhang X; Zhou C; Cao J; Zhou T
    J Glob Antimicrob Resist; 2023 Dec; 35():172-180. PubMed ID: 37716532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
    Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
    Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales.
    Lu G; Tang H; Xia Z; Yang W; Xu H; Liu Z; Ni S; Wang Z; Shen J
    Infect Drug Resist; 2022; 15():7107-7116. PubMed ID: 36506837
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
    Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial peptide WAM-1: a promising antibacterial and anti-inflammatory drug against carbapenem-resistant Klebsiella pneumoniae.
    Zhang X; Shi S; Yao Z; Zheng X; Li W; Zhang Y; Wang L; Cao J; Zhou T
    J Antimicrob Chemother; 2022 Jun; 77(7):1903-1911. PubMed ID: 35474013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KPC-2 allelic variants in
    Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
    Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
    Huang YT; Kuo YW; Teng LJ; Liao CH; Hsueh PR
    J Glob Antimicrob Resist; 2021 Sep; 26():301-307. PubMed ID: 34303027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibacterial activity and mechanism of a novel peptide MR-22 against multidrug-resistant
    Tian C; Zhao N; Yang L; Lin F; Cai R; Zhang Y; Peng J; Guo G
    Front Cell Infect Microbiol; 2024; 14():1334378. PubMed ID: 38328670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of ceftazidime/avibactam resistance in drug-naïve bacteraemic Enterobacterales strains without metallo-beta-lactamase production: Associated with ceftazidime impedance.
    Xiong L; Wang Y; Wang X; Zhou Y; Chi X; Chen T; Lu P; Chen Y; Ji J; Xiao Y
    Int J Antimicrob Agents; 2023 Aug; 62(2):106877. PubMed ID: 37271474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
    Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Borde K; Kareem MA; Sharma RM; Dass SM; Ravi V; Mathai D
    Microbiol Spectr; 2023 Sep; 11(5):e0084723. PubMed ID: 37737637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.